Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cost-effectiveness of thrombolytics: a simplified model.

Sule Apikoğlu Rabuş1, Fikret Vehbi Izzettin, Mesut Sancar

  • 1Clinical Pharmacy Department, Faculty of Pharmacy, Marmara University, Tibbiye Cad. no 49, Haydarpasa, 34817, Istanbul, Turkey.

Pharmacy World & Science : PWS
|August 13, 2005
PubMed
Summary

Tissue plasminogen activator (TPA) offers a 2.37% survival benefit over streptokinase (SK) for acute myocardial infarction (AMI) patients in Turkey. However, TPA

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Factors related to community pharmacists' intention to provide collaborative deprescribing service for fall-risk medications in older adults: a factorial and theory-based cross-sectional study.

International journal of clinical pharmacy·2026
Same author

Pharmacists's knowledge, attitude, and practices towards pharmaceutical and patient-centred care in asthma management: A national study.

Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society·2026
Same author

Impact of clinical pharmacist interventions on drug-related problems in hospitalised patients with renal dysfunction: a quasi-experimental study.

Scientific reports·2026
Same author

Dynamic aortic stiffness response to exercise as a marker of functional capacity in early-stage heart failure.

Clinical physiology and functional imaging·2026
Same author

Impact of Pharmacist-Led Antimicrobial Stewardship on Antibiotic Use in Intensive Care: A Prospective Audit and Feedback Approach.

Journal of the American College of Clinical Pharmacy : JACCP·2026
Same author

Impact of clinical pharmacist-led behavioural theory-based discharge service to promote medication adherence in patients with acute coronary syndrome: a randomised controlled trial.

International journal of clinical pharmacy·2026

Area of Science:

  • Pharmacoeconomics
  • Health Economics
  • Cardiology

Background:

  • Acute myocardial infarction (AMI) poses a significant health burden.
  • Thrombolytic therapy, including tissue plasminogen activator (TPA) and streptokinase (SK), is a critical treatment for AMI.
  • Evaluating the cost-effectiveness of different treatment options is crucial for healthcare decision-making.

Purpose of the Study:

  • To develop a model for retrospective cost-effectiveness analysis.
  • To determine the incremental cost-effectiveness ratio (ICER) of TPA compared to SK in Turkey.
  • To inform healthcare decision-makers about the economic value of TPA for AMI treatment.

Main Methods:

  • A retrospective analysis was conducted at Koşuyolu Heart, Education and Research Hospital, Istanbul, Turkey.

Related Experiment Videos

  • 196 patients with AMI were randomly selected; one-year mortality rates were compared between TPA, SK, and other treatment groups.
  • Pharmacoeconomic analysis involved 28 surviving patients from TPA and 28 from SK groups, using medical records and hospital bills for cost data.

    • Main Results:

    • TPA demonstrated a 2.37% increase in one-year survival rate compared to SK.
    • The incremental cost-effectiveness ratio (ICER) for TPA over SK was calculated at €47,289 ($49,180.6) per life saved.
    • The increased cost associated with TPA was €1120.8 ($1165.6) per patient.

    Conclusions:

    • The developed model serves as a guide for similar cost-effectiveness analyses.
    • The findings provide valuable information for Turkish decision-makers assessing the medical benefit versus cost of TPA.
    • This study contributes to the existing literature on the cost-effectiveness of thrombolytic therapies for AMI.